Generic Drug Co. Can Continue Arbitration Against Ranbaxy
A Texas appellate court on Monday allowed a generic drug developer to move forward in arbitration with claims it had been fraudulently induced to assign patent rights to Ranbaxy Inc., reversing...To view the full article, register now.
Already a subscriber? Click here to view full article